[go: up one dir, main page]

MX2019001804A - Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. - Google Patents

Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2019001804A
MX2019001804A MX2019001804A MX2019001804A MX2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A MX 2019001804 A MX2019001804 A MX 2019001804A
Authority
MX
Mexico
Prior art keywords
neurodegenerative disorders
modified peptides
treating neurodegenerative
treating
peptides
Prior art date
Application number
MX2019001804A
Other languages
English (en)
Other versions
MX393805B (es
Inventor
Garcia-Rates Sara
MORAL Jesus
COSANO Roger
Greenfield Susan
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Publication of MX2019001804A publication Critical patent/MX2019001804A/es
Publication of MX393805B publication Critical patent/MX393805B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a trastornos neurodegenerativos, y en particular a novedosos péptidos, peptidomiméticos, composiciones, tratamientos y métodos para tratar tales afecciones, por ejemplo, la enfermedad de Alzheimer.
MX2019001804A 2016-08-16 2017-08-16 Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. MX393805B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1613999.0A GB201613999D0 (en) 2016-08-16 2016-08-16 Neurodegenerative disorders
GBGB1701455.6A GB201701455D0 (en) 2016-08-16 2017-01-30 Neurodegenerative disorders
PCT/GB2017/052407 WO2018033724A1 (en) 2016-08-16 2017-08-16 Modified peptides for use in treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
MX2019001804A true MX2019001804A (es) 2019-07-01
MX393805B MX393805B (es) 2025-03-24

Family

ID=56985964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001804A MX393805B (es) 2016-08-16 2017-08-16 Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.

Country Status (13)

Country Link
US (1) US11939398B2 (es)
EP (1) EP3500252B1 (es)
JP (1) JP7125143B2 (es)
KR (1) KR102457935B1 (es)
CN (1) CN109640972B (es)
AU (1) AU2017313372B2 (es)
BR (1) BR112019003189A2 (es)
CA (1) CA3033497A1 (es)
ES (1) ES2930320T3 (es)
GB (2) GB201613999D0 (es)
MX (1) MX393805B (es)
RU (1) RU2756052C2 (es)
WO (1) WO2018033724A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201613999D0 (en) 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
GB202306126D0 (en) 2023-04-26 2023-06-07 Neuro Bio Ltd Treatment of rapamycin-sensitive conditions
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
ATE384077T1 (de) 1999-05-05 2008-02-15 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
IL147970A0 (en) 1999-08-09 2002-09-12 Tripep Ab Pharmaceutical compositions containing tripeptides
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
JP4010951B2 (ja) 2001-05-15 2007-11-21 大正製薬株式会社 アルギニン誘導体
JP2004155695A (ja) * 2002-11-06 2004-06-03 Taisho Pharmaceut Co Ltd Ｍｃ４受容体に対するリガンド
US20050159362A1 (en) 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
JP2006347951A (ja) 2005-06-16 2006-12-28 Yoshihiro Futamura 神経細胞活性化作用を有するトリペプチド、それからなる食品製剤、化粧品及び抗認知症剤
GB2432586B (en) * 2005-11-25 2010-01-13 Univ Open Treatment of neurodegenerative disorders
WO2013103634A2 (en) 2012-01-03 2013-07-11 Yu Ruey J N-acylpeptide derivatives and their uses
GB2516045A (en) * 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
GB201613999D0 (en) 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders

Also Published As

Publication number Publication date
KR102457935B1 (ko) 2022-10-21
MX393805B (es) 2025-03-24
JP7125143B2 (ja) 2022-08-24
RU2019103805A (ru) 2020-09-21
KR20190039271A (ko) 2019-04-10
AU2017313372A1 (en) 2019-03-07
ES2930320T3 (es) 2022-12-09
CN109640972B (zh) 2023-05-26
AU2017313372B2 (en) 2022-12-22
RU2756052C2 (ru) 2021-09-24
WO2018033724A1 (en) 2018-02-22
RU2019103805A3 (es) 2020-10-30
CN109640972A (zh) 2019-04-16
GB201701455D0 (en) 2017-03-15
JP2019532028A (ja) 2019-11-07
BR112019003189A2 (pt) 2019-11-26
EP3500252B1 (en) 2022-11-02
US11939398B2 (en) 2024-03-26
EP3500252A1 (en) 2019-06-26
US20210094983A1 (en) 2021-04-01
GB201613999D0 (en) 2016-09-28
CA3033497A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
MX378940B (es) Trastornos neurodegenerativos.
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2019000047A (es) Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX2018003174A (es) Metodos para tratar enfermedades inflamatorias.
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
IL263433A (en) Methods for treating alzheimer's disease
EA201791937A1 (ru) Противовоспалительные полипептиды
MX373409B (es) Composiciones para fibras de queratina.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EP3538219A4 (en) TOPICAL COMPOSITION FOR TREATING ACNE
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
MX2019001804A (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
BR112019007214A2 (pt) composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos